Taiho has reupped its commitment to the venture firm’s second fund, which is also backed by EA Pharma and Senju and which has closed at $95m.

UGA spinout Aruna Bio is working on a treatment for neurodegenerative diseases such as Parkinson’s and multiple sclerosis.

Vision Fund 2 participated in a series B round for the gene therapy developer, formed through the 2019 merger of Torque Therapeutics and Cogen Immune Medicine.

Vizgen co-founder David Walt, a professor at Harvard Medical School, has invested in the spinout as part of its series B round.

Gene therapy developer Jaguar has completed a series B round co-led by Eli Lilly and Deerfield Management.

SafeGuard Cyber has raised $45m in a Cisco-backed debt and equity round while Pine Labs has paid the same amount to buy portfolio company Fave.

The infectious disease drug developer has applied to float in Hong Kong, which will enable the WuXi AppTec-backed 6 Dimensions Capital to exit.

The personalised dental care provider increased its overall funding to almost $200m in a GV-backed series C round.

The drug discovery platform developer will support its growth with new funding from investors including SIG and Legend Capital.

Evotec has partnered Bristol-Myers Squibb to launch a $20m commercialisation programme aimed at academic institutions in Germany’s Rhine-Main-Neckar region.